2015 I CORPORATE PRESENTATION
HOPE, it’s what Sanofi brings each day,
responding to the new challenges
of protecting the h...
SANOFI AT A GLANCE
OUR HERITAGE
OUR STRATEGY
OUR COMMITMENTS
OUR 3 BUSINESS SEGMENTS
OUR INNOVATION IN R&D
OUR RESPONSIBIL...
SANOFI
AT A GLANCE
3
© Denis Felix
CORPORATE PRESENTATION – JUNE 11, 2015
SANOFI AT A GLANCE
OUR
HERITAGE
A long tradition
in health
4
Hoechst
Marion
Roussel
1997
Roussel
1911
Marion
1950
Hoechst
...
SANOFI AT A GLANCE
OUR
STRATEGY
5
SEIZEVALUE-ENHANCING
GROWTH OPPORTUNITIES
ADAPTSTRUCTURE FOR
FUTURE CHALLENGES
& OPPORTU...
SANOFI AT A GLANCE
6
Our mission
We act with our partner to protect health, enhance life
and respond to the hopes and pote...
SANOFI AT A GLANCE
OUR MISSION
We act with our partners
to protect health, enhance life,
provide hope and respond
to the p...
SANOFI AT A GLANCE
OUR
COMMITMENTS
8
1
EXPLORING
THE BOUNDARIES
OF MEDICAL INNOVATION
Sanofi is committed to a more open
a...
SANOFI AT A GLANCE
OUR
COMMITMENTS
9
2
PREVENTING DISEASES
AND SUPPORTING PATIENTS
Improved quality of life and longer lif...
SANOFI AT A GLANCE
© Denis Felix
OUR
COMMITMENTS
10
3
IMPROVING ACCESS
TO HEALTHCARE
Healthcare needs vary from continent
...
SANOFI AT A GLANCE
OUR
3 BUSINESS
SEGMENTS
11
HUMAN
VACCINES
>Pediatric vaccines
>Influenza vaccines
>Booster vaccines
for...
SANOFI AT A GLANCE
OUR
INNOVATION
IN R&D
12
€4.8bn
Invested in R&D
in 2014
5
R&D HUBS
Across Europe,
North America
and Asi...
SANOFI AT A GLANCE
CORPORATE
SOCIAL
RESPONSIBILITY
13
© Pierre–Olivier/Capa Pictures
Each day, across the globe,
Sanofi’s ...
SANOFI AT A GLANCE
14
Improve access to medicines in the most
deprived countries with an access to medicines
department wh...
SANOFI AT A GLANCE
OUR
KEY FIGURES
2014
15
BY ACTIVITIES
(in million euros)
BY GEOGRAPHICAL AREA
(in million euros)
EMPLOY...
SANOFI AT A GLANCE
OUR
PRESENCE
16
In more than
100 countries
107
Industrial sites
in 40 countries
More than
20
R&D sites
...
RECOMMENDATIONS
Forward Looking Statements
This document contains forward-looking statements as defined in the Private Sec...
Further information:
www.sanofi.com
SANOFI
COMMUNICATION CORPORATE
54, rue La Boétie
75008 Paris, France
Tel. +33 (0)1 53 ...
Prochain SlideShare
Chargement dans…5
×

Sanofi - Corporate Presentation

87 371 vues

Publié le

Sanofi - Corporate Presentation

Publié dans : Santé & Médecine
0 commentaire
4 j’aime
Statistiques
Remarques
  • Soyez le premier à commenter

Aucun téléchargement
Vues
Nombre de vues
87 371
Sur SlideShare
0
Issues des intégrations
0
Intégrations
65 560
Actions
Partages
0
Téléchargements
119
Commentaires
0
J’aime
4
Intégrations 0
Aucune incorporation

Aucune remarque pour cette diapositive

Sanofi - Corporate Presentation

  1. 1. 2015 I CORPORATE PRESENTATION HOPE, it’s what Sanofi brings each day, responding to the new challenges of protecting the health of seven billion people VIDEO HOPE © Denis FelixJune 11, 2015
  2. 2. SANOFI AT A GLANCE OUR HERITAGE OUR STRATEGY OUR COMMITMENTS OUR 3 BUSINESS SEGMENTS OUR INNOVATION IN R&D OUR RESPONSIBILITY OUR KEY FIGURES OUR PRESENCE CORPORATE PRESENTATION – JUNE 11, 2015 2
  3. 3. SANOFI AT A GLANCE 3 © Denis Felix CORPORATE PRESENTATION – JUNE 11, 2015
  4. 4. SANOFI AT A GLANCE OUR HERITAGE A long tradition in health 4 Hoechst Marion Roussel 1997 Roussel 1911 Marion 1950 Hoechst 1863 Synthélabo 1970 Delalande 1924 Delagrange 1931 Robert & Carrière 1901 Dausse 1834 BMP Sunstone, Medley, Merial, Nepentes, Zentiva, Kendricks, Oenobiol, Chattem, Acambis, Symbion, Shantha Biotechnics , Fovea, Bipar Sciences, Targegen, Genfar, Globalpharma 2008-2015 Genzyme 2011 Sanofi-aventis 2004 Aventis 1999 Sanofi-Synthélabo 1999 Sanofi Pasteur 2004 Sterling 1901 Midy 1718 Clin Midy 1971 Chinoin 1919 Sanofi 1973 Connaught 1922 Rorer 1910 Rhône-Poulenc Rorer 1990 Institut Mérieux 1897 Wittman & Poulenc 1860 CORPORATE PRESENTATION – JUNE 11, 2015
  5. 5. SANOFI AT A GLANCE OUR STRATEGY 5 SEIZEVALUE-ENHANCING GROWTH OPPORTUNITIES ADAPTSTRUCTURE FOR FUTURE CHALLENGES & OPPORTUNITIES BRINGINNOVATIVE PRODUCTS TO MARKET Delivering sustainable long-term growth by: GROWA GLOBAL HEALTHCARE LEADER WITH SYNERGISTIC PLATFORMS © Guillaume Ramon/Capa Pictures CORPORATE PRESENTATION – JUNE 11, 2015
  6. 6. SANOFI AT A GLANCE 6 Our mission We act with our partner to protect health, enhance life and respond to the hopes and potential healthcare needs of 7 billion people around the world. 3 business segments Pharma Human vaccines Animal Health 3 Commitments Exploring the boundaries of medical innovation for patients Preventing disease and supporting patients Improving access to healthcare More than 110,000 employees Present in 100 countries €33.8 bn In sales 2014 CORPORATE PRESENTATION – JUNE 11, 2015
  7. 7. SANOFI AT A GLANCE OUR MISSION We act with our partners to protect health, enhance life, provide hope and respond to the potential healthcare needs of 7 billion people around the world. With our global footprint and commitment to improving access to medicines and healthcare, we work tirelessly to make a difference to people’s lives every day and transform scientific innovations into therapeutic solutions for patients. 7 © G. Blonsky/Capa Pictures CORPORATE PRESENTATION – JUNE 11, 2015
  8. 8. SANOFI AT A GLANCE OUR COMMITMENTS 8 1 EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION Sanofi is committed to a more open and productive Research & Development model, focused on patient needs and based on biotechnology. This model significantly accelerates the pace and enhances the productivity of research, driving the development of more effective health solutions in major therapeutic areas. Between 2014 and 2020, more than 18 potential launches are anticipated. © Pierre-Olivier/Capa Pictures CORPORATE PRESENTATION – JUNE 11, 2015
  9. 9. SANOFI AT A GLANCE OUR COMMITMENTS 9 2 PREVENTING DISEASES AND SUPPORTING PATIENTS Improved quality of life and longer life expectancy, coupled with increased prevalence of chronic disease are contributing to the evolution of today’s main healthcare challenges. Sanofi promotes prevention through vaccination and support for patients. The Group’s commitment goes beyond a medication: it is based on understanding and listening to patients to provide integrated health solutions and personalized treatment. © Pierre-Olivier/Capa Pictures CORPORATE PRESENTATION – JUNE 11, 2015
  10. 10. SANOFI AT A GLANCE © Denis Felix OUR COMMITMENTS 10 3 IMPROVING ACCESS TO HEALTHCARE Healthcare needs vary from continent to continent. While the northern hemisphere is marked by an aging population, the southern is characterised by demographic growth, urbanization, and a rise in chronic diseases. To meet the many different healthcare needs of the seven billion inhabitants of our planet and improve their access to treatment, Sanofi has established a global presence in more than 100 countries, a specific product portfolio for each market and a leadership position in Emerging markets. CORPORATE PRESENTATION – JUNE 11, 2015
  11. 11. SANOFI AT A GLANCE OUR 3 BUSINESS SEGMENTS 11 HUMAN VACCINES >Pediatric vaccines >Influenza vaccines >Booster vaccines for adults and adolescents >Meningitis vaccines >Vaccines for travelers and endemic areas ANIMAL HEALTH PHARMA PRODUCTS >Anti-parasitics >Anti-infectives >Anti-inflammatories >Anti-ulceratives VACCINES >Foot and mooth disease >Rabies and pets vaccines Range >Avian vaccines PHARMA >Diabetes >Cardiovascular disease >Rare diseases >Multiple sclerosis >Oncology >Consumer Health care >Generics Net sales €27,720 M Net sales €3,974 M Net sales €2,076 M © G. Blonsky/Capa Pictures CORPORATE PRESENTATION – JUNE 11, 2015
  12. 12. SANOFI AT A GLANCE OUR INNOVATION IN R&D 12 €4.8bn Invested in R&D in 2014 5 R&D HUBS Across Europe, North America and Asia-Pacific 43 molecules and vaccines in the R&D portfolio including 14 in late stage* Up to 18 launches expected between 2014 and 2020 *Annual results, Feb. 2015 Diabetes Toujeo Afrezza Lixilan Lyxumia Insulin pro Uncontrolled Hypercholesterolemia Praluent® Pediatric Vaccines Shan 5 PR5i-6-1 Rotavirus vaccine Rare disease Familial amyloid polyneuropathy Patisiran Dengue Dengue vaccine Clostridum Difficile C.Diff vaccine Multiple Sclerosis Lemtrada Oncology SAR650984 Type 1 Gaucher disease Cerdelga Severe asthma dupilumab Dogs Fleas and ticks Nexgard® Rheumatoid arthritis sarilumab CORPORATE PRESENTATION – JUNE 11, 2015
  13. 13. SANOFI AT A GLANCE CORPORATE SOCIAL RESPONSIBILITY 13 © Pierre–Olivier/Capa Pictures Each day, across the globe, Sanofi’s 110,000 employees are working to protect the health and improve access to healthcare for as many patients as possible. As a healthcare company, Sanofi places quality, safety, ethics, and respect for the planet at the heart of its business. More than 300 access to healthcare programs in more than 80 countries 1/3 of the global population has no access to healthcare More than 190 million people benefited PARTNERING TO PROMOTE ACCESS TO HEALTHCARE CORPORATE PRESENTATION – JUNE 11, 2015
  14. 14. SANOFI AT A GLANCE 14 Improve access to medicines in the most deprived countries with an access to medicines department whose holistic approach acts on several levels: > Tiered-pricing for affordable medicines > Information, training and education programs > Innovative research > Partnerships on the ground to ensure program success Reduce health inequalities through its ’programs dedicated to: > Childhood cancer > Maternal and neonatal mortality > Access to healthcare for the world’s most needy communities. Promoting quality care by fighting against counterfeit medicines. CORPORATE SOCIAL RESPONSIBILITY © Rémi DUHAMEL - Image in Production CORPORATE PRESENTATION – JUNE 11, 2015
  15. 15. SANOFI AT A GLANCE OUR KEY FIGURES 2014 15 BY ACTIVITIES (in million euros) BY GEOGRAPHICAL AREA (in million euros) EMPLOYEES BY ACTIVITIES EMPLOYEES BY GEOGRAPHICAL AREA €33.8 bn Net sales Animal Health 2,076 Pharma 27,720 Vaccines 3,974 More than 110,000 employees worldwide United States 11,339 Other countries 3,219 Emerging markets 11,347 Western Europe 7,865 Animal Health 6,109 Pharma 93,393 Vaccines 13,994 Other countries 41,528 North America 18,627Europe 53,341 Emerging Markets: The world excluding the United States, Canada, Western Europe, Japan, Australia and New Zealand. CORPORATE PRESENTATION – JUNE 11, 2015
  16. 16. SANOFI AT A GLANCE OUR PRESENCE 16 In more than 100 countries 107 Industrial sites in 40 countries More than 20 R&D sites worldwide CLOSER TO OUR PATIENTS AND PARTNERS EUROPE 48 Manufacturing sites 6 Development centers 33 Distribution Hubs NORTH AMERICA 19 Manufacturing sites 2 Development centers 8 Distribution Hubs ASIA-PACIFIC 20 Manufacturing sites 5 Development centers 30 Distribution Hubs LATIN AMERICA 12 Manufacturing sites 3 Development centers 30 Distribution Hubs AFRICA-MIDDLE-EAST 8 Manufacturing sites 1 Development center 58 Distribution Hubs CORPORATE PRESENTATION – JUNE 11, 2015
  17. 17. RECOMMENDATIONS Forward Looking Statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward- looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 17 This corporate presentation is available for all employees of the Sanofi Group. It may be used internally or externally for presentations of the Group, either in whole or in part, as needed. The information is taken from Sanofi’s annual report on Form 20-F 2014, annual results 2014 and press releases. Further information is available on www.sanofi.com CORPORATE PRESENTATION – JUNE 11, 2015
  18. 18. Further information: www.sanofi.com SANOFI COMMUNICATION CORPORATE 54, rue La Boétie 75008 Paris, France Tel. +33 (0)1 53 77 40 00 CORPORATE PRESENTATION 2015 18

×